FinnCap reaffirmed their buy rating on shares of Cello Group (LON:CLL) in a research note published on Monday. The firm currently has a GBX 135 ($1.82) price objective on the stock.

Separately, N+1 Singer reissued a buy rating and set a GBX 131 ($1.76) target price on shares of Cello Group in a report on Wednesday, September 20th.

Cello Group (LON CLL) opened at GBX 124.25 ($1.67) on Monday. Cello Group has a 12-month low of GBX 95.20 ($1.28) and a 12-month high of GBX 140 ($1.88).

In related news, insider Mark Bentley sold 150,450 shares of the business’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of GBX 126 ($1.70), for a total transaction of £189,567 ($255,137.28).

TRADEMARK VIOLATION WARNING: “FinnCap Reiterates “Buy” Rating for Cello Group (CLL)” was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/finncap-reiterates-buy-rating-for-cello-group-cll/1750754.html.

Cello Group Company Profile

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with Analyst Ratings Network's FREE daily email newsletter.